If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksACC.L Regulatory News (ACC)

  • There is currently no data for ACC

Trading Update

9 Dec 2020 17:31

RNS Number : 1355I
Access Intelligence PLC
09 December 2020
 

Prior to publication, certain information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of this announcement, this information is now considered to be in the public domain.

 

Access Intelligence plc

("Access Intelligence" or the "Company")

Trading Update

 

 

Access Intelligence (AIM: ACC), the technology innovator delivering Software-as-a-Service ("SaaS") solutions for the PR, communications and marketing industries, announces an update on trading for year ended 30 November 2020.

 

The Company's growth rate has more than doubled in the second half of the year with strong new business and renewal rates underpinning excellent growth in Annual Contract Value ('ACV') of £2.82m. This compares to ACV growth of £1.06m in the first six months of the financial year, with all sub-brands seeing growth acceleration in the second half. New business sales in the year increased by 95 per cent. year on year and upsell increased by 52 per cent. year on year. Total ACV at 30 November 2020 was approximately £21.9 million.

 

New clients wins in the second half include Amazon, Automobili Lamborghini, Boots, British Retail Consortium, Comic Relief, European Food Safety Authority, Hulu, LinkedIn, Linklaters, McLaren Racing, Publicis, Saatchi & Saatchi, Unicredit and Veolia. The wins continue to demonstrate the increasing appeal of the Company's product portfolio across different sectors and territories.

 

The Board expect that total revenue for the financial year will be in the order of £19.1 million, compared to £13.4 million for the prior year.

 

Given the circumstances created by COVID 19, the year saw the board take a number of cost saving initiatives including the Company furloughing approximately 15% of staff, salary and fee reductions for the Board and employees for three months, and the curtailment of discretionary spending. Notwithstanding the global economic challenges faced in the year, the Board is delighted with the excellent growth trajectory demonstrated by the Company in the year and the Board remains focused on delivering against the longer-term growth opportunity. As part of this strategy the Board actively looks to explore new business opportunities through product enhancement and new technologies to complement the Group's suite of products. This strategy seeks to deliver organic growth complemented by acquisitions to capitalise on opportunities which enable the Group to accelerate its market position. In the course of this year, the Company has incurred non recurring costs of £2.4m including £1.2m of costs incurred as it evaluated potential M&A activity in-line with this strategy.

 

The Company continues to be in a good financial position and as at 30 November, net cash was approximately £1.4 million. In order to underpin the Group's finances and provide additional liquidity, the Company has secured a £2 million, three year facility under the Coronavirus Business Interruption Loan Scheme (CBILS). The facility can be drawn down during December 2020, has a 12-month interest-free period following drawdown and an interest rate of 2.03% plus LIBOR or replacement benchmark rate per annum on the drawn down amount thereafter. The funds are repayable in equal monthly instalments over 36 months and there will be no penalty for making early repayment of the facility. In addition, as the Company looks to accelerate its growth, the Company is separately announcing a placing to raise approximately £10 million today.

 

Christopher Satterthwaite, Non-Executive Chairman of the Company, said: 

"We reported 10% organic ACV growth in 2019 and saw that rise to 12% in the first half of 2020, in spite of the global COVID pandemic. Delivering annualised ACV growth of 30% in the second half of 2020 is an excellent achievement.

 

We've achieved these results thanks to colleagues adapting quickly and readily to new ways of working in challenging circumstances. I cannot praise their energy, focus and flexibility highly enough.

 

This positive performance demonstrates the strength of our product portfolio and our increasing global market presence.

 

We will be starting the financial year 2021 with confidence and a strong pipeline of opportunities."

 

For further information:

Access Intelligence plc 020 3426 4024

Joanna Arnold (CEO) / Mark Fautley (CFO)

finnCap Limited (Nominated Adviser and Broker) 020 7220 0500

Corporate Finance:

Marc Milmo / Kate Bannatyne / Kate Washington

Corporate Broking:

Alice Lane / Sunila de Silva

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFSSFWUESSEDE
Date   Source Headline
1st Feb 20182:36 pmRNSTotal Voting Rights
29th Jan 201812:22 pmRNSHolding(s) in Company
23rd Jan 20181:58 pmRNSHolding(s) in Company
5th Jan 20184:24 pmRNSHolding(s) in Company
3rd Jan 20183:21 pmRNSHolding(s) in Company
29th Dec 20177:00 amRNSConversion of Loan Notes
21st Nov 20172:20 pmRNSHolding(s) in Company
20th Nov 20177:00 amRNSTrading Update
10th Nov 201710:26 amRNSDirectorate Change
18th Oct 20178:53 amRNSHolding(s) in Company
25th Aug 20177:00 amRNSInterim results for 6 months to 31 May 2017
31st Jul 20175:00 pmRNSTotal Voting Rights
26th Jul 201712:28 pmRNSDirector/PDMR Shareholding
25th Jul 20171:08 pmRNSHolding(s) in Company
24th Jul 201712:03 pmRNSHolding(s) in Company
24th Jul 201710:10 amRNSHolding(s) in Company
18th Jul 20177:00 amRNSSubscription to raise £1,020,000
26th May 20173:05 pmRNSResult of AGM
11th May 20176:09 pmRNSDirector/PDMR Shareholding
9th May 20174:00 pmRNSHolding(s) in Company
2nd May 20172:02 pmRNSDirectorate Change
2nd May 20177:00 amRNSFinal Results
21st Mar 20174:26 pmRNSSale of AI ControlPoint Limited
7th Feb 20172:03 pmRNSIssue of Equity
31st Jan 20179:43 amRNSHolding(s) in Company
3rd Jan 201710:21 amRNSHolding(s) in Company
28th Dec 20163:28 pmRNSExtension of Convertible Loan Notes
18th Oct 20166:00 pmRNSHolding(s) in Company
17th Aug 20167:00 amRNSUnaudited results for 6 months ended 31 May 2016
2nd Aug 20166:30 pmRNSHolding(s) in Company
4th Jul 20167:00 amRNSDisposal
9th May 20165:11 pmRNSHolding(s) in Company
5th May 20162:52 pmRNSResult of AGM
22nd Apr 20164:18 pmRNSRedemption of £0.9m of 2015 Loan Notes
20th Apr 20167:00 amRNSHolding(s) in Company
11th Apr 20167:00 amRNSPreliminary results for the y/e 30 November 2015
14th Mar 20167:00 amRNSChange of Adviser
23rd Feb 20164:54 pmRNSHolding(s) in Company
3rd Feb 20167:00 amRNSDisposal of Due North
23rd Dec 20151:03 pmRNSIssue of Equity
30th Nov 20152:20 pmRNSChange of Registered Office
25th Nov 20157:00 amRNSHolding(s) in Company
30th Oct 20158:26 amRNSHolding(s) in Company
6th Oct 20151:46 pmRNSHolding(s) in Company
1st Oct 20158:00 amRNSDirector/PDMR Shareholding
24th Aug 20157:00 amRNSInterim Results
5th Aug 20157:00 amRNSIssue of Equity
8th Jul 201511:30 amRNSHolding(s) in Company
1st Jul 20157:00 amRNSTotal Voting Rights
24th Jun 20157:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.